Abstract: Systems and methods are provided for screening histopathology tissue samples. An anomaly detection system is trained on a plurality of training images. Each of the plurality of training images represents a tissue sample that is substantially free of abnormalities. A test image, representing a tissue sample, is provided to the anomaly detection system. A deviation from normal score is generated for at least a portion of the test image. The deviation from normal score represents a degree of abnormality in the tissue sample represented by the test image.

Abstract: Systems and methods are provided for screening a set of histopathology tissue samples representing a region of interest for abnormalities. A pattern recognition classifier is trained on a first set of images, each representing a tissue sample that is substantially free of abnormalities, and a second set of images, each representing one of the set of histopathology tissue samples representing the region of interest. At least one performance metric from the pattern recognition classifier is generated. A given performance metric represents one of an accuracy of the classifier in discriminating between images representing tissue that is substantially free of abnormalities and images of histopathology tissue samples representing the region of interest and a training rate of the pattern recognition classifier. A likelihood of abnormalities in the region of interest is determined from the at least one performance metric from the pattern recognition classifier.

Abstract: Systems and methods are provided for screening histopathology tissue samples. An anomaly detection system is trained on a plurality of training images. Each of the plurality of training images represents a tissue sample that is substantially free of abnormalities. A test image, representing a tissue sample, is provided to the anomaly detection system. A deviation from normal score is generated for at least a portion of the test image. The deviation from normal score represents a degree of abnormality in the tissue sample represented by the test image.

Abstract: The present invention relates to the discovery that increases in invariant NKT cell (iNKT) number and/or activity can reduce the incidence or severity of metabolic disorders such as obesity and diabetes. The invention accordingly features methods, kits, and compositions for the treatment of such metabolic disorders by administration of a composition capable of increasing iNKT activity.

Abstract: The present invention relates to the discovery that increases in invariant NKT cell (iNKT) number and/or activity can reduce the incidence or severity of metabolic disorders such as obesity and diabetes. The invention accordingly features methods, kits, and compositions for the treatment of such metabolic disorders by administration of a composition capable of increasing iNKT activity.

Abstract: A compound of formula (I) is described in which each A, which may be the same or different, is a halide selected from fluoride, chloride, bromide and iodide, or is O—Y, wherein Y is a substituted or unsubstituted, saturated or unsaturated, straight or branched chain alkyl moiety. R1, R2, R3, R6, R7, and R8 are each independently H, OH, NO2 or O-L-X, wherein L is a spacer group, and X is a conjugation group or a water-solubilizing group. At least one of R1, R2, R3 is OH or O-L-X and at least one of R6, R7, and R8 is OH or O-L-X. R4 and R5, which may be the same or different, are each independently H; or are a substituted or unsubstituted, saturated or unsaturated, cyclic moiety; a substituted or unsubstituted, saturated or unsaturated heterocyclic moiety; or a substituted or unsubstituted, saturated or unsaturated, straight or branched chain alkyl moiety. Also described are dye conjugates comprising a compound of the invention.

Abstract: The present invention relates to the discovery that increases in invariant NKT cell (iNKT) number and/or activity can reduce the incidence or severity of metabolic disorders such as obesity and diabetes. The invention accordingly features methods, kits, and compositions for the treatment of such metabolic disorders by administration of a composition capable of increasing iNKT activity.

Abstract: A compound of formula (I) is described in which each A, which may be the same or different, is a halide selected from fluoride, chloride, bromide and iodide, or is O—Y, wherein Y is a substituted or unsubstituted, saturated or unsaturated, straight or branched chain alkyl moiety. R1, R2, R3, R6, R7, and R8 are each independently H, OH, NO2 or O-L-X, wherein L is a spacer group, and X is a conjugation group or a water-solubilizing group. At least one of R1, R2, R3 is OH or O-L-X and at least one of R6, R7, and R8 is OH or O-L-X. R4 and R5, which may be the same or different, are each independently H; or are a substituted or unsubstituted, saturated or unsaturated, cyclic moiety; a substituted or unsubstituted, saturated or unsaturated heterocyclic moiety; or a substituted or unsubstituted, saturated or unsaturated, straight or branched chain alkyl moiety. Also described are dye conjugates comprising a compound of the invention.

Abstract: In one aspect, the present invention provides a method for detecting an expression level of a cell surface marker in a sample, comprising staining the sample with a reagent that labels the cell surface marker; obtaining an image of the stained sample; and determining a value for continuity of cell surface staining in the image, wherein the value is indicative of the expression level.

Abstract: The present invention relates to compounds of the formula or a salt, metal complex or hydrate or other solvate thereof, wherein: M is a chelating agent; R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of: H; a substituted or unsubstituted, saturated or unsaturated, cyclic, moiety; a substituted or unsubstituted, saturated or unsaturated, heterocyclic moiety; or a substituted or unsubstituted, saturated or unsaturated, straight or branched chain alkyl or acyl moiety; and R2and R5 may also be independently a heavy atom or a water-solubilizing group. The present invention also relates to use of these compounds in the therapy in vivo or in vitro of a photosensitive target biological cell by irradiation, as well as methods of treating a photosensitive target biological cell in vivo or in vitro. Finally, the present invention relates to pharmaceutical compositions, comprising these compounds, in association with a pharmaceutically acceptable diluent or carrier.

Abstract: The disclosed technology can detect objectionable content in a displayed image. Pixel groupings associated with the displayed image can be analyzed in response to one or more intercepted messages associated with a window that displays the image and a probability that the displayed image includes objectionable content can be subsequently computed. This probability can serve as a basis for classifying the displayed image as objectionable.

Abstract: The present invention relates to compounds of the formula or a salt, metal complex or hydrate or other solvate thereof, wherein: M is a chelating agent; R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of: H; a substituted or unsubstituted, saturated or unsaturated, cyclic, moiety; a substituted or unsubstituted, saturated or unsaturated, heterocyclic moiety; or a substituted or unsubstituted, saturated or unsaturated, straight or branched chain alkyl or acyl moiety; and R2 and R5 may also be independently a heavy atom or a water-solubilizing group. The present invention also relates to use of these compounds in the therapy in vivo or in vitro of a photosensitive target biological cell by irradiation, as well as methods of treating a photosensitive target biological cell in vivo or in vitro. Finally, the present invention relates to pharmaceutical compositions, comprising these compounds, in association with a pharmaceutically acceptable diluent or carrier.